Table 4 TC, IC and CPS of tissue samples of the index patients before and after nivolumab therapy
From: Therapeutic implications of PD-L1 expression in bladder cancer with squamous differentiation
Type | squamous component | 28–8 | 22C3 | SP263 | SP142 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
IC% | TC% | CPS | IC% | TC% | CPS | IC% | TC% | CPS | IC% | TC% | CPS | ||
TUR-B 82 months | 80% | 30 | 1 | 30 | 30 | 1 | 30 | 25 | 7 | 30 | 7 | 0 | 7 |
Cystx 101 months | 15% | 10 | 0 | 10 | 10 | 0 | 10 | 10 | 0 | 10–12 | 7 | 0 | 7 |